This page shows the latest ESMO 2012 news and features for those working in and with pharma, biotech and healthcare.
The new data from the EMILIA study were presented yesterday at the European Society for Medical Oncology (ESMO) annual meeting, and come from a study involving patients with HER2-positive breast ... 2nd October 2012.
Ariad’ s lung cancer drug impresses at ESMO. Early stage trials demonstrate potential in hard-to-treat patients. ... Presenting data at the annual congress of the European Society for Medical Oncology (ESMO 20120) in Vienna, Austria, Ariad said that an
Merck already sells Erbitux as a treatment for metastatic colorectal cancer and squamous cell carcinoma of the head and neck, bringing in 430m in the first six months of 2012, but ... The data will be presented at the European Society for Medical
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
ESMO 2012 Video and Social Media Highlights. Brandcast Health's take on the highlights from the ESMO 2012 congress in Vienna, Austria, including social media insights.
More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.